Zhiyang Zhao

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Alliance Pharma. Dr. Zhao has over 25 years of pharmaceutical industry experience with a special focus on metabolic and pharmacokinetic properties of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Alliance Pharma, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade.

Dr. Zhao’s extensive experience spans the entire drug discovery and development process (discovery, development, and in-/out-licensing) in oncology, metabolic, antiviral, CNS, and inflammatory diseases. Dr. Zhao’s contributions and accomplishments of integrating into Vitro and in vivo ADMET (absorption, distribution, metabolism, excretion, and toxicity) information to optimize drug candidate properties are documented in over 50 peer‑reviewed scientific publications and patents in the areas of new drug targets, drug metabolism, pharmacokinetics, and toxicology.